Subcutaneous Leuprolide Acetate Shows Promise for Treatment of CPP
Researchers demonstrate the gonadotropin-releasing hormone agonist implant’s ability to control precocious puberty.
All articles by Endocrinology Advisor Contributing Writer
Systematic Review of Nonpharmacologic Osteoporosis Treatment Guidelines
Researchers performed a systematic review of clinical practice guidelines to identify nonpharmacologic recommendations for osteoporosis treatment.
Bempedoic Acid Plus Ezetimibe Lowers LDL-C When Added to Maximally Tolerated Statin Therapy
Fixed-dose bempedoic acid with ezetimibe lowered LDL-C vs placebo when added to maximally tolerated statin therapy in patients with high CVD risk and hypercholesterolemia.
Predictors of Complication Screening Uptake in Type 1 Diabetes
Patients who attended complication screenings paid more visits to diabetes clinics within the first 2 years after diagnosis, had higher median lifetime HbA1c, and had less socioeconomic disadvantage.
Early Treatment for Hyperthyroidism Reduces CV Morbidity, Mortality in Graves Disease
Early and intensive treatment for hyperthyroidism in Graves disease is associated with improvements in cardiovascular morbidity and all-cause mortality, regardless of treatment method used.
Effects of Offering Breakfast in the Classroom on Child Obesity
Offering breakfast in the classroom increased the number of students participating in the subsidized school food program but also increased incidence and prevalence of obesity.
β-Cell Function in Youth With Impaired Glucose Tolerance, T2D
Investigators examined whether β-cell function can be improved or preserved with antihyperglycemic agents in young patients.
Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
Investigators reviewed cases of patients with multiple sclerosis treated with alemtuzumab to determine the type and frequency of thyroid dysfunction.
Revised Pooled Cohort Equations for CVD Risk Improve Accuracy of Estimates
Investigators revised pooled cohort equations to improve clinical accuracy to predict risk for cardiovascular disease.
IDegLira: A Cost-Effective Alternative to Basal-Bolus Therapy in T2D
IDegLira is a cost-effective alternative to basal bolus insulin therapy with insulin glargine U100 plus insulin aspart.
-
Loading...
-
Loading...
Next post in Type 2 Diabetes
